Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 10
Pharmacogenomics of sickle cell disease: steps toward personalized medicine
Authors Husain M, Hartman AD, Desai P
Received 10 June 2017
Accepted for publication 9 August 2017
Published 19 October 2017 Volume 2017:10 Pages 261—265
DOI https://doi.org/10.2147/PGPM.S123427
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Martin Bluth
Marium Husain,1 Amber D Hartman,2 Payal Desai3
1Division of Medical Oncology, 2Division of Palliative Medicine, 3Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Abstract: Sickle cell disease (SCD) is a monogenetic disease but has a wide range of phenotypic expressions. Some of these differences in phenotype can be explained by genetic polymorphisms in the human globin gene. These polymorphisms can result in different responses to typical treatment, sometimes leading to inadequate therapeutics. Research is revealing more polymorphisms, and therefore, new targets for intervention to improve outcomes in SCD. This area of pharmacogenomics is continuing to develop. We provide a brief review of the current literature on pharmacogenomics in SCD and possible targets for intervention.
Keywords: sickle cell disease, pharmacogenomics, hydroxyurea, opioids, HbF inducers, gene therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.